Sanofi increases Lantus investment in China

Published: 21-Apr-2009
Regulatory Research & Development

Sanofi-Aventis is to invest US$90m to boost output of the insulin Lantus in China.


Sanofi-Aventis is to invest US$90m to boost output of the insulin Lantus in China.

The French pharmaceutical company says local production of Lantus (insulin glargine) will begin by 2012.

The new commitment follows a US$94m investment Sanofi made in 2007 to build a manufacturing facility for products that prevent seasonal influenza. Taken together the two investments make the company the biggest investor in China's biological field.

Sanofi has also formed a partnership with the Chinese Diabetes Society to initiate a diabetes genotyping project involving more than 46,000 diabetic and non-diabetic patients. This study will analyse in-depth genetic factors to understand better the pathogenesis of type 2 diabetes, which could allow people at risk of developing the disease to be detected early and define effective risk prevention strategies.

  • Companies:
  • Sanofi
See more

You may also like

Regulatory

MHRA's approval of Sanofi's Teplizumab signals a new era in type 1 diabetes management

Read more
Imagine delaying a life-altering chronic illness. Teplizumab offers precious time, potentially freeing eligible individuals and their families from the immediate and overwhelming demands of T1D

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

MHRA's approval of Sanofi's Teplizumab signals a new era in type 1 diabetes management

Imagine delaying a life-altering chronic illness. Teplizumab offers precious time, potentially freeing eligible individuals and their families from the immediate and overwhelming demands of T1D
Research & Development

Sanofi to acquire immunology-focused biopharma company, Blueprint Medicines

The acquisition will allow Sanofi access to Blueprint's rare immunology disease pipeline — a current key focus for the company
Research & Development

Sanofi to acquire neurodegenerative disease biotech, Vigil Neuroscience for $470m

The acquisition will boost Sanofi's neurology pipeline — one of its key disease focus areas
Manufacturing

Sanofi to invest $20bn into US manufacturing capacity following Trump's tariff threats

The company will expand its US pharmaceutical R&D and manufacturing capacity through internal and contract manufacturing investments
Regulatory

Sanofi's BTK inhibitor rilzabrutinib granted FDA orphan drug designation

Rilzabrutinib has already received orphan drug designation from the EU and Japan for use in patients with immune thrombocytopenia
Regulatory

Sanofi's Novolog biosimilar Merilog gets the FDA green light

The biosimilar improves glycaemic control in diabetic patients by lowering blood sugar spikes, and is the first fast-acting insulin analog to be approved in the US
Research & Development

Sanofi and Orano Med join forces to develop next-gen oncology medicines

The companies will combine their biotech and R&D expertise to develop rare cancer-targeting radioligand therapies (RLTs)
Subscribe now